A recent study found that the highest driver of a physicians choice of treatment was reduction in percentage of body surface area affected, overall perception of fficacy, and maintenance of response
104 A novel anticancer drug carrier has been presented
Medical Supervision All therapy is physician-directed with regular metabolic monitoring and dose optimization for safety and efficacy
432 A 2021 systematic review and meta-analysis that included 22 observational studies with a total of 440,281 elderly participants with atrial fibrillation taking rivaroxaban, dabigatran, apixaban, or edoxaban found these medications were associated with similar reductions in risks of stroke and other embolic events, but rivaroxaban was associated with more bleeding events than apixaban or edoxaban
O'Mahoney LL, Matu J, Price OJ, et al